Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
| ▸ | F10 | P00742 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3609921 | 0.90 | ROCK2 (0.78) | ROCK2LMNAROCK1CYP3A4CYP2C9 | |
| SCHEMBL10198258 | 0.87 | ROCK2 (0.67) | ROCK2LMNAROCK1CYP3A4CYP2C9 | |
| SCHEMBL305398 | 0.81 | ROCK2 (0.78) | ROCK2LMNAROCK1CYP3A4CYP2C9 | |
| SCHEMBL305141 | 0.81 | ROCK2 (0.78) | ROCK2LMNAROCK1CYP3A4CYP2C9 | |
| SCHEMBL307152 | 0.80 | ROCK2 (1.00) | ROCK2LMNAROCK1CYP3A4SMN1; SMN2 | |
| SCHEMBL1719761 | 0.79 | MAPK1 (0.58) | LMNACYP3A4CYP2C9ALDH1A1SMN1; SMN2 | |
| SCHEMBL7681303 | 0.79 | LMNA (0.90) | LMNAALDH1A1NR1H4SMN1; SMN2 | |
| SCHEMBL306304 | 0.78 | ROCK2 (0.70) | ROCK2LMNAROCK1CYP3A4CYP2C9 | |
| SCHEMBL307259 | 0.78 | ROCK2 (0.73) | ROCK2CYP3A4SMN1; SMN2 | |
| SCHEMBL13947481 | 0.77 | MMP13 (0.60) | ROCK2LMNAROCK1MMP13F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041645-A1 | RHO KINASE INHIBITORS | CIT, ROCK1, RHOT2 | ROCK2 4/4885LMNA 2642/4885ROCK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.